Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush
Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report report published on Monday morning,RTT News reports. Wedbush currently ...
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...